Home Test Search Results Factor XII (12) Inhibitor Titer
Factor XII (12) Inhibitor Titer

Justification

Acquired factor deficiencies may occur due to the development of factor-specific inhibitory antibodies. These antibodies may also develop against factor replacement products in patients with a congenital deficiency. This test may be used to detect and quantitate inhibitory antibodies against Factor XII.

STAT: < 24 hours (7 days a week)

Bethesda, Clot-based

Draw Tube: Blue Top

Sample Type: Citrated Plasma

Specimen Requirements

Sample Type Volume Required Minimum Volume Stability
PREFERRED Citrated Plasma Two aliquots, 1mL each Two aliquots, 0.5mL each Frozen (-20C): 2 weeks
Frozen (-80C): 6 months
ALTERNATIVE - - - -
REJECTION CRITERIA Thawed in transit, refrozen or clotted sample
SPECIAL INSTRUCTIONS -

General Information

METHODOLOGY Bethesda, Clot-based
STAT TAT < 24 hours (7 days a week)
STAT TAT Performance > 90% of results released in 24 hours 7 days a week
ROUTINE TAT < 3 days (M-F)
ALTERNATIVE NAMES Hageman Factor inhibitor, F12 inhibitor, FXII inhibitor
DESCRIPTION Bethesda titer for the quantitative determination of a specific factor inhibitor against factor XII (12).
LIMITATIONS -
NORMAL RANGE < 0.4 BU
ASSOCIATED TESTING -
REFERENCES -
SAMPLE REPORT Upon request
NEW YORK STATE APPROVED No

Test Codes

ORDER CODE P3417
CPT CODE 85280, 85335
LOINC CODE 3232-6